概要

Metrics for Return on Engagement in Patient-Centered Drug Development Conference

Our first-ever Metrics in Patient-Centered Drug Development Conference!

The medical products industry is at a critical juncture, with an opportunity to define medical product development operational activities and measures that will support the growth of patient centricity. The Metrics in Patient-Centered Drug Development Conference will examine the core principles of measuring the return on engagement (ROE) of patient engagement and demonstrate how current and emerging approaches are being applied by industry colleagues to measure engagement impact on outcomes of importance to patient, industry, regulatory, and payer stakeholders. Lessons learned will provide a valuable resource for attendees addressing challenges and resolving problems in the design and implementation of their own patient-centric initiatives and ROE measures.

Featured

Want to learn more about Metrics in Patient-Centered Drug Development Conference? You've come to the right site!

参加対象

Patient Organizations
Payers
Regulatory Agency Reviewer and Decision-Makers

Biopharmaceutical and Medical Device Professionals involved in:

Patient Advocacy/Engagement/Experience/Access (Including Chief Patient Officers)
Patient Communications
Medical Affairs and Medical Communications (Including Chief Medical Officers)
Health Outcomes
Study Endpoint Development
Clinical Trial Design and Optimization
Clinical Research and Clinical Operations
Benefit-Risk Assessment
Pharmacovigilance and Risk Management
Medical Science Liaisons
C-Suite Executives, Global Heads, Senior Directors, and Other Decision-Makers

学習目的

At the conclusion of this conference, participants should be able to:

Describe the current policy landscape for patient engagement in the medical product development life cycle and its impact on the needs of industry stakeholders in measuring engagement outcomes
Assess areas of commonality and divergence among key needs of patient, regulatory, industry, and payer stakeholders in the medical product life cycle as a basis for strategizing measures of return on engagement
Discuss how to apply current and emerging approaches to measurement of engagement outcomes and ROE
Assimilate lessons learned on “what worked” for early adopters in order to anticipate potential challenges and optimize outcomes and ROE

プログラム委員会

Marc M. Boutin, JD Global Head of Patient Engagement and Advocacy
Novartis , Switzerland
Ellen Coleman, MPH, MS President and Chief Executive Officer
VOZ Advisors, United States
Kenneth Getz, MBA Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States
Elizabeth Lincoln, MA HR Consultant
CCI Consulting, United States
K. Kimberly McCleary Founder and Chief Executive Officer
The Kith Collective, LLC, United States
Roslyn Schneider, MD, FACP Vice President, Head of Global Patient Affairs
Biomarin Pharmaceuticals Inc., United States
Suzanne Schrandt, JD Founder, Chief Executive Office and Chief Patient Advocate
ExPPect, United States

Digital Learning Catalog

Download

Metrics in Patient-Centered Drug Development Conference

概要